Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures

Matthew Austin, Yu-Ching Yang, Eric Vittinghoff, Silvano Adami, Steven Boonen, Douglas C Bauer, Gerolamo Bianchi, Michael A Bolognese, Claus Christiansen, Richard Eastell, Andreas Grauer, Federico Hawkins, David L Kendler, Beatriz Oliveri, Michael R McClung, Ian R Reid, Ethel S Siris, Jose Zanchetta, Cristiano A F Zerbini, Cesar Libanati, Steven R Cummings, FREEDOM Trial, Matthew Austin, Yu-Ching Yang, Eric Vittinghoff, Silvano Adami, Steven Boonen, Douglas C Bauer, Gerolamo Bianchi, Michael A Bolognese, Claus Christiansen, Richard Eastell, Andreas Grauer, Federico Hawkins, David L Kendler, Beatriz Oliveri, Michael R McClung, Ian R Reid, Ethel S Siris, Jose Zanchetta, Cristiano A F Zerbini, Cesar Libanati, Steven R Cummings, FREEDOM Trial

Abstract

Dual-energy X-ray absorptiometric bone mineral density (DXA BMD) is a strong predictor of fracture risk in untreated patients. However, previous patient-level studies suggest that BMD changes explain little of the fracture risk reduction observed with osteoporosis treatment. We investigated the relevance of DXA BMD changes as a predictor for fracture risk reduction using data from the FREEDOM trial, which randomly assigned placebo or denosumab 60 mg every 6 months to 7808 women aged 60 to 90 years with a spine or total hip BMD T-score < -2.5 and not < -4.0. We took a standard approach to estimate the percent of treatment effect explained using percent changes in BMD at a single visit (months 12, 24, or 36). We also applied a novel approach using estimated percent changes in BMD from baseline at the time of fracture occurrence (time-dependent models). Denosumab significantly increased total hip BMD by 3.2%, 4.4%, and 5.0% at 12, 24, and 36 months, respectively. Denosumab decreased the risk of new vertebral fractures by 68% (p < 0.0001) and nonvertebral fracture by 20% (p = 0.01) over 36 months. Regardless of the method used, the change in total hip BMD explained a considerable proportion of the effect of denosumab in reducing new or worsening vertebral fracture risk (35% [95% confidence interval (CI): 20%-61%] and 51% [95% CI: 39%-66%] accounted for by percent change at month 36 and change in time-dependent BMD, respectively) and explained a considerable amount of the reduction in nonvertebral fracture risk (87% [95% CI: 35% - >100%] and 72% [95% CI: 24% - >100%], respectively). Previous patient-level studies may have underestimated the strength of the relationship between BMD change and the effect of treatment on fracture risk or this relationship may be unique to denosumab.

© 2012 American Society for Bone and Mineral Research

Figures

Fig. 1
Fig. 1
Relationship between new or worsening vertebral fracture incidence at 36 months and percent change from baseline in total hip BMD at 36 months. Adjusted estimates for a baseline lumbar spine BMD T-score of −2.5. Data represent the 5th through the 95th percentiles of total hip BMD percent change. The density curves at the bottom represent the distributions of total hip BMD change at 36 months for each treatment group. For both denosumab and placebo, the risk of new or worsening vertebral fracture decreased with increasing percent change in total hip BMD but the slope of the curves differed between treatment groups (interaction p value = 0.0003).
Fig. 2
Fig. 2
Relationship between nonvertebral fracture incidence at 36 months and percent change from baseline in total hip BMD at 36 months. Adjusted estimates for a baseline total hip BMD T-score of −2.5. Data represent the 5th through the 95th percentiles of total hip BMD percent change. The density curves at the bottom represent the distributions of total hip BMD change at 36 months for each treatment group. For both denosumab and placebo, the risk of nonvertebral fracture decreased with increasing percent change in total hip BMD. The data suggest similar relationships (slopes) for both treatment groups (interaction p value = 0.38).

References

    1. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254–9.
    1. Bruyere O, Roux C, Badurski J, Isaia G, de Vernejoul MC, Cannata J, Ortolani S, Slosman D, Detilleux J, Reginster JY. Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate. Curr Med Res Opin. 2007;23:3041–5.
    1. Bruyere O, Roux C, Detilleux J, Slosman DO, Spector TD, Fardellone P, Brixen K, Devogelaer JP, Diaz-Curiel M, Albanese C, Kaufman JM, Pors-Nielsen S, Reginster JY. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab. 2007;92:3076–81.
    1. Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res. 2006;21:1785–90.
    1. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002;112:281–9.
    1. Li Z, Meredith MP, Hoseyni MS. A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med. 2001;20:3175–88.
    1. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res. 2002;17:1–10.
    1. Wasnich R, Miller PD, Chesnut CH, Huss H, Wilson K, Schimmer RC. Changes in bone mineral density as a predictor of vertebral fracture efficacy with lbandronate: results from a phase III fracture study. J Bone Miner Res. 2003;18:S160.
    1. Watts NB, Cooper C, Lindsay R, Eastell R, Manhart MD, Barton IP, van Staa TP, Adachi JD. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom. 2004;7:255–61.
    1. Watts NB, Geusens P, Barton IP, Felsenberg D. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res. 2005;20:2097–104.
    1. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab. 2000;85:231–6.
    1. Delmas PD, Li Z, Cooper C. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. J Bone Miner Res. 2004;19:330–7.
    1. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 2002;87:1586–92.
    1. Compston J. Monitoring osteoporosis treatment. Best Pract Res Clin Rheumatol. 2009;23:781–8.
    1. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337–42.
    1. Kostenuik PJ. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol. 2005;5:618–25.
    1. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756–65.
    1. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354:821–31.
    1. Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone HG. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24:153–61.
    1. Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25:72–81.
    1. Seeman E, Delmas PD, Hanley DA, Sellmeyer D, Cheung AM, Shane E, Kearns A, Thomas T, Boyd SK, Boutroy S, Bogado C, Majumdar S, Fan M, Libanati C, Zanchetta J. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res. 2010;25:1886–94.
    1. Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48:677–92.
    1. Genant HK, Engelke K, Hanley DA, Brown JP, Omizo M, Bone HG, Kivitz AJ, Fuerst T, Wang H, Austin M, Libanati C. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone. 2010;47:131–9.
    1. Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, Barrett-Connor E, Musliner T, Thompson D. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum. 1999;42:1246–54.
    1. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963–74.
    1. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. Berlin: Springer; 2000.
    1. Harrell FE. Regression modeling strategies: with applications to linear models, logistic regresiion, and survival analysis. Berlin: Springer; 2001.
    1. Lin DY, Fleming TR, De Gruttola V. Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med. 1997;16:1515–27.
    1. Keaveny T, McClung M, Genant H, Zanchetta J, Kendler D, Brown JP, Goemaere S, Recknor C, Brandi ML, Eastell R, Engelke K, Fuerst T, Radcliffe H, Libanati C. Denosumab improves both femoral and vertebral strength in women with osteoporosis: results from the FREEDOM Trial. J Bone Miner Metab. 2010;25(Suppl 1):S31.
    1. Genant H, Engelke K, Zanchetta JR, Hoiseth A, Yuen CK, Stonkus S, Bolognese M, Franek E, Fuerst T, Radcliffe H-S, Libanati C, McClung M. Hip QCT results from the FREEDOM Trial: evidence for positive BMD/BMC changes in integral, trabecular, and cortical bone with denosumab. J Bone Miner Metab. 2010;25(Suppl 1):S127–8.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe